Study on efficacy and safety of the simultaneous treatment with febuxostat and inosine of patients with Parkinson's disease.

Not Applicable

• Conditions: Parkinson' s disease

• Registration Number: JPRN-UMIN000030930
• Lead Sponsor: StaGen Co. Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-10-03
• Study Start: 2019-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patient who requires nearly full assistance in one's daily life, is incapable of walking and standing (2) Patient taking azathioprine, mercaptopurine hydrate, vidarabine or didanosine (3) Patient whose serum creatinine exceeds 1.5 times the upper limit of the reference value or whose AST (GOT) or ALT (GPT) exceeds the upper limit of the reference value in the pre-registration examination (4) Patient who has undergone surgical treatment for Parkinson's disease (5) Patient with a history or a current illness of gout, hyperuricaemia or urolithiasis (6) Patient who has been treated with febuxostat (7) Patient who has a history or a present illness of hypersensitivity / Idiosyncratic reaction (allergy) to a drug or drugs (8) Patient who has used an investigational drug within 30 days before the consent (9) Patient with pregnancy or a possibility of pregnancy, or lactating patient (10) Patient judged inappropriate with other reasons by a principal investigator or a subinvestigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified